IL-17
Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies
Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.
Axial Spondyloarthritis Agents: Dr Antoni Chan
Dr. Chan reviews several abstracts #1366, #1367 and #1364 at the 2020 ACR annual meeting.
Juan Camilo Sarmiento-Monroy jcsam25
4 years 7 months ago
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
SKIPPAIN Trial: Dr. Sheila Reyes
Dr. Sheila Reyes reviews abstract #0899 presented at the 2020 ACR annual meeting.
Nomenclature, Uveitis and Other Spondyloarthritis Features: Dr. Lianne Gensler
Dr. Gensler reviews her top selections for ACR 2020 today, including abstract #0881 and #0876. She also highlighted the study group on spondyloarthritis, which focused on nomenclature.
Olga Petryna DrPetryna
4 years 7 months ago
@RheumNow #acr20 abs0876 gender differences AS and nrSpA from 3 RCT IXE trials: F more likely to be older, have more nocturnal BP, peripheral pain&fatigue. M have higher CRP & +HLAB27. Ant uveitis > in M w/AS (23.8% vs. 17.9%) but > common in F w/ nr-axSpA (15.2% vs. 7.1%). https://t.co/HZa7AfWbBh
Robert B Chao, MD doctorRBC
4 years 7 months ago
Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko
Dr. Rachel Tate uptoTate
4 years 7 months ago
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Robert B Chao, MD doctorRBC
4 years 7 months ago
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Dr. Antoni Chan synovialjoints
4 years 7 months ago
Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366
Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52.
Robert B Chao, MD doctorRBC
4 years 7 months ago
Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting.
Here is a flavour of my read through the topics that are being covered during the meeting.
Non-radiographic axSpa ACR Abstracts: Dr. Rachel Tate
Dr. Rachel Tate discusses abstracts #0876 and #0448 presented at the ACR20 annual meeting.
Poster Hall